Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Superoxide anion (O-2) is the first metabolite of the monocyte oxygen burst pathway, which plays an important role in the monocyte microbicidal function. The capacity of peripheral blood monocytes to produce O-2 was studied in 63 patients with Hodgkin's disease (31 with active disease and 32 in complete remission), 15 patients with active malignant lymphoma, and 57 normal control subjects. O-2 release was quantified by evaluating superoxide dismutase-inhibitable reduction of cytochrome c after stimulation of monocytes with phorbol myristate acetate. Results were expressed in nanomols O-2 per mg protein per hour. O-2 production was lower than normal in patients with active Hodgkin's disease (163.3 v 214.5, P less than .05). It was normal in patients with Hodgkin's disease in complete remission (216.2 v 214.5, P greater than .05) and high in patients with malignant lymphomas (317.9 v 214.5, P less than .01). Within the group with active Hodgkin's disease, patients in relapse after therapy had a lower O-2 production than those previously untreated (99.8 v 181.8, P less than .01). Stage of disease was unrelated to the defect. The presence of B symptoms and a decreased delayed type hypersensitivity to recall skin test antigens were associated with normal O-2 production. The results obtained suggest that monocyte dysfunction is part of the immune dysregulation associated with active Hodgkin's disease. The O-2 determination is a relatively easy test to perform and may be useful in identifying the patients with Hodgkin's disease who have an increased risk of opportunistic infections.
 ...
PMID:Superoxide anion (O-2) production by peripheral blood monocytes in Hodgkin's disease and malignant lymphoma. 298 22

Endoxan (cyclophosphamide) is a cyclic propylene phosphamide ester of nitrogen mustard. Endoxan--main advantage of chemotherapy is complete penetration of the tissues, reaching the most widely spread malignant cells. It is one of the most useful cytotoxics available today. Endoxan is a "transport form" and as such it has a selective tumour affinity. Endoxan is used for active treatment of all neoplastic diseases of the reticulo-endothelial system, e.g. lymphomas, lymphosarcomas, reticular-sarcomas, Hodgkin's disease, chronic lymphatic leukaemias, multiple myelomas. In our experiments Endoxan is equivalent with mean therapeutic the concentration used in chemotherapy in tumours, we suppose that at these levels Endoxan interact with renal cells and probably induce or inhibits new generation of superoxide free forms in the same tissue. Endoxan was tested at renal supernatant and free enzyme model systems, for superoxide-scavenging and antioxidante activity. The ability of Endoxan to interact with the superoxide radical, to influence their generation and probably to change the levels of lipid peroxidation in model systems were investigated. The ability of Endoxane to affect Fe2+-induced lipid peroxidation in a renal supernatant was studied. The results show that Endoxan in a concentration range of 10(-4); 10(-5) M has small but significant effect. The values for the control samples without Endoxan, are compared. We found a dose-dependent superoxide-scavenging effect of the drug in xanthite/xanthine oxidase system for generation of superoxide. According to obtained results lndoxan could be used in insertion in a liposomes and this could impact lndoxan tissue penetration.
 ...
PMID:Effects of endoxan on oxidative processes in model systems in vitro. 1892 76